PRKAA1 and fatty liver disease: Since AMPK maintains metabolic homeostasis through the regulation of various downstream pathways [30], activation of this molecule is considered a promising therapeutic target for many diseases associated with excessive lipid synthesis, such as obesity, hyperlipidemia, and fatty liver disease [31].